Kardigan (KARD) Registration filing summary

Company overview and business model

• Clinical-stage precision therapeutics company focused on developing medicines targeting root causes of specific cardiovascular diseases with no approved treatments.

• Pipeline includes three late-stage programs: Danicamtiv (genetic DCM), Ataciguat (moderate CAVS), and Tonlamarsen (post-hospitalization management of ASH).

• Proprietary Prolaio platform integrates real-world patient data and advanced analytics to optimize clinical trial design and execution.

• Business model leverages parallel development of targeted therapies and technology-driven trial acceleration.

Financial performance and metrics

• No revenue generated to date; company remains pre-commercial.

• Net loss of $191.9 million for 2025 and $88.7 million for 2024; accumulated deficit of $337.2 million as of March 31, 2026.

• Research and development expenses were $153.1 million in 2025, up from $84.3 million in 2024.

• Cash, cash equivalents, and short-term investments totaled $287.1 million as of March 31, 2026.

• Management and auditors have raised substantial doubt about the company’s ability to continue as a going concern, even after the IPO.

Use of proceeds and capital allocation

• Estimated net proceeds from IPO: $320.3 million (or $369.1 million if underwriters exercise their option in full), assuming a $15.00/share price.

• Proceeds intended to fund clinical development of Danicamtiv, Ataciguat, and Tonlamarsen, other R&D activities, and general corporate purposes.

• Expected to fund operations into 2028, but additional capital will be required for full development and commercialization.